3D bioprinting lab to be set up at TCD by AMBER and Johnson & Johnson
21 February 2018
AMBER partners with multinational healthcare company to create global 3D bioprinting collaborative laboratory at Trinity College Dublin
Dr Lorraine Byrne; Minister Heather Humphreys; Dr Gráinne Cunniffe; and Prof Mark Ferguson
AMBER has unveiled a strategic collaboration with Johnson & Johnson to establish a collaborative laboratory focused on 3D bioprinting at Trinity College Dublin. AMBER will also engage in research projects focused initially in orthopaedics and, in the long term, offer its internal scientific experts as adjunct professors and engage in staff exchanges.
The new 3D bioprinting lab is due to be operational by the end of 2018.
The focus for the new research laboratory will be 3D bioprinting, co-led by AMBER’s Professor Daniel Kelly and Joseph Ault, senior fellow, Lead API and Bioprinting at Johnson & Johnson. The collaborative laboratory will establish a work space for Johnson & Johnson scientists and Trinity academicians to engage in collaborative research.
3D bioprinting has emerged as a promising technology for engineering 3D ‘living’ biological tissues for promoting bone and tissue regeneration.
The laboratory will be made available to other principal investigators, postgraduate and undergraduate students to carry out project work outside of the direct collaborative activity with Prof Kelly. This will benefit students by providing exposure to industry and the potential to source industry-defined projects. In addition, Johnson & Johnson scientists will be available to provide training and education to students and staff.
A 100m2 space within Trinity Biomedical Sciences Institute building identified
The AMBER team has identified a 100m2 space within the Trinity Biomedical Sciences Institute (TBSI) building, comprising lab area suitable for working with bioprinting and cell and tissue culture and meeting and office space for 12 people. In addition to the new lab, the investment will enable a number of individual research projects and long-term scale-up to include adjunct professorships and staff exchange.
Work on the new laboratory will begin in Q1 2018, with Trinity graduate and AMBER postdoctoral researcher Dr Gráinne Cunniffe employed by Johnson & Johnson as project manager for the lab. AMBER will provide full support to the project in terms of project management, funding diversification support, recruitment and contract support as is standard with the Centre’s operating model.
This collaboration is strongly aligned with AMBER’S vision to be a world leader in bioengineering and Trinity’s vision to establish a new Engineering, Energy and Environment (E3) Institute and a technology campus at Dublin’s Grand Canal to be an incubation site for companies to embed significant research and innovation activities at the University and engage in multi-faculty collaborations.
Result of a shared vision
Professor Michael Morris, AMBER director said: “This lab is the result of a shared vision to create a global centre of excellence for 3D bioprinting within the centre. This has been made possible because of the calibre of our world leading academics, state of the art equipment and supporting facilities and infrastructure.
“Building on our long-standing collaboration with DePuy Synthes in Ireland, I am confident that this engagement will become the prototypical strategic partnership for AMBER as the Centre moves into the next funding cycle. Our intent is to identify and grow similar engagements of equivalent scale and type across the ICT and manufacturing sectors.”
Professor Mark Ferguson, director general of Science Foundation Ireland and chief scientific adviser to the government said: “I very much welcome this promising collaboration between AMBER and Johnson & Johnson Services, which builds on Ireland’s international reputation for research excellence and presents us with an important opportunity to promote the sharing of knowledge and expertise between industry and academia – in material sciences and beyond.”
Minister for Business, Enterprise and Innovation, Heather Humphreys TD said: “AMBER has a worldwide reputation for excellence in 3D bioprinting and is a global leader in materials science. I am delighted to welcome this new collaboration and look forward to its success moving forward.”
“Transforming healthcare delivery for patients and consumers through 3D printing technology requires collaboration with experts from around the world,” said Wim Appelo, vice-president supply chain, Johnson & Johnson Medical Devices Companies. “Our work with AMBER will advance opportunities to design and deliver a broad range of personalised, bioprinted healthcare solutions for the patients and consumers we serve every day.”https://www.engineersjournal.ie/2018/02/21/3d-bioprinting-lab-tcd-amber-johnson-johnson/https://www.engineersjournal.ie/wp-content/uploads/2018/02/am-1-1024x683.jpghttps://www.engineersjournal.ie/wp-content/uploads/2018/02/am-1-300x300.jpgNews3D Printing,AMBER,SFI,TCD